BCL2 and in situ carcinoma: HDACi’s have also been shown to modulate the expression of Bcl-2 family proteins including Bcl-2 and Bcl-xL23–25, therefore we evaluated pano as a senolytic therapy to eliminate CIS, and monitored acetylated H3 in these populations as a surrogate for drug effect.